---
title: "002007.SZ (002007.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002007.SZ/news.md"
symbol: "002007.SZ"
name: "002007.SZ"
parent: "https://longbridge.com/en/quote/002007.SZ.md"
datetime: "2026-03-12T12:52:03.141Z"
locales:
  - [en](https://longbridge.com/en/quote/002007.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002007.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002007.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/002007.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002007.SZ/news.md)


# 002007.SZ (002007.SZ) — Related News

### [The quadrivalent influenza vaccine will exit the market this year](https://longbridge.com/en/news/278210880.md)
*2026-03-07T10:03:28.000Z*
> The quadrivalent influenza vaccine will exit the market during the 2026-2027 Northern Hemisphere flu season. The World H

### [HUALAN BIOLOGICAL: Pembrolizumab injection approved to conduct clinical trials](https://longbridge.com/en/news/276868869.md)
*2026-02-25T10:12:03.000Z*
> HUALAN BIOLOGICAL announced that its investee, Hualan Ankang Biological Co., Ltd., has been approved by the National Med

### [HUALAN BIOLOGICAL: Investee company receives notification of drug clinical trial approval](https://longbridge.com/en/news/276867991.md)
*2026-02-25T10:05:04.000Z*
> HUALAN BIOLOGICAL announced that on February 25, 2026, its affiliated company HUALAN ANKANG BIOLOGICAL CO., LTD. receive

### [CITIC Construction Investment | 2025 Overview of the Blood Products Industry: The proportion of domestic albumin batch approvals increases, and the development of new products continues to advance](https://longbridge.com/en/news/276006811.md)
*2026-02-15T13:13:05.000Z*
> The research report from CITIC Construction Investment Securities indicates that the domestic blood products industry wi

### [PLBIO: The clinical trial application for the registration of human thrombin drug has been accepted](https://longbridge.com/en/news/274935360.md)
*2026-02-05T08:01:11.000Z*
> PLBIO announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the "Acc

### [HUALAN BIOLOGICAL: The company currently has no drugs related to the prevention of Nipah virus](https://longbridge.com/en/news/274769837.md)
*2026-02-04T07:10:45.000Z*
> On February 4th, HUALAN BIOLOGICAL stated on the interactive platform that the company currently has no drugs related to

### [HUALAN BIOLOGICAL: Reorganization of Exendin-4-Fc fusion protein injection approved for clinical trials](https://longbridge.com/en/news/274625168.md)
*2026-02-03T08:53:19.000Z*
> HUALAN BIOLOGICAL announced that the company has received approval from the National Medical Products Administration to 

### [Henan Listed Companies ESG-V Rating: Leading Enterprises Show Outstanding Value Capability, Environmental Management Remains a Weakness | Listed Company Observation](https://longbridge.com/en/news/274471135.md)
*2026-02-02T06:24:33.000Z*
> The ESG-V ratings of listed companies in Henan show that leading enterprises excel in value capability, but environmenta

### [Pre-market announcement gold mining: Maximum expected increase of 903%! Last night, companies with explosive performance clustered together, with 5 companies forecasting a year-on-year net profit increase of over 300% for 2025](https://longbridge.com/en/news/273299811.md)
*2026-01-22T00:58:49.000Z*
> TFC expects a net profit growth of 40%-60% year-on-year in 2025; NMS signed a equipment contract worth 296 million yuan;